Patients

our desire to
transform lives
drives our work

We are dedicated to developing innovative microbiome therapeutics that have the potential to transform lives.

Each day we are working with urgency to develop therapeutics for a wide range of conditions linked to a disrupted gut microbiome, the community of microbes that live in our gut, starting with recurrent C. difficile infection, autism spectrum disorder, inflammatory bowel disease, and chronic hepatitis B.

To learn more about our work and find out if we are currently recruiting participants for a clinical trial you or a loved one may be interested in, please see below.

Recurrent C. diff

We are developing CP101, an orally administered microbiome product candidate for the prevention of recurrent C. difficile (C. diff) infection. CP101 is designed to deliver a full community of beneficial bacteria to the areas of the intestine affected by C. diff.

CP101 for the prevention of recurrent C. diff is currently in late-stage clinical development and we are planning a confirmatory Phase 3 clinical trial. When additional information is available about our trial plans, we will share an update on our website.

Autism spectrum disorder

We are developing FIN-211, an orally administered microbiome product candidate for the treatment of children with autism and serious gastrointestinal symptoms.

FIN-211 is currently in the pre-clinical development phase, meaning that we have not yet started clinical (in-human) trials to evaluate safety and efficacy. When additional information is available about our trial plans, we will share an update on our website.

Inflammatory bowel disease

In collaboration with Takeda Pharmaceuticals, we are developing FIN-524 and FIN-525, orally administered microbiome product candidates, for the treatment of inflammatory bowel disease (IBD).

Our investigational drugs for IBD are currently in the pre-clinical development phase, meaning that we have not yet started clinical (in-human) trials to evaluate safety and efficacy.

Chronic hepatitis B

We are developing CP101, an orally administered microbiome product candidate for the treatment of chronic hepatitis B (HBV). CP101 is designed to facilitate viral clearance by delivering an intact microbiome community that stimulates the immune system.

CP101 for the treatment of chronic HBV is currently in the pre-clinical development phase, meaning that we have not yet started clinical (in-human) trials to evaluate safety and efficacy.